Friday, 16 October 2026European Markets

VÅR ENERGI And PANORO ENERGY Have A High Dividend Yield And Return On Equity In The Oil & Gas E&P Industry.

Loading stream...

(VIANEWS) - VÅR ENERGI (VAR.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Oil & Gas E&P industry.

Financial Asset Price Forward Dividend Yield Return on Equity
VÅR ENERGI (VAR.OL) kr26.04 15.93% 47.67%
PANORO ENERGY (PEN.OL) kr26.90 0.93% 11.06%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. VÅR ENERGI (VAR.OL)

15.93% Forward Dividend Yield and 47.67% Return On Equity

Vår Energi AS, an independent upstream oil and gas company, explores for, develops, and produces hydrocarbons. The company operates four fields on the Norwegian continental shelf, including the Goliat, Marulk, Balder, and Ringhorne and Ringhorne East fields located in the Barents, the Norwegian, and the North Sea, as well as holds ownership interests in 32 producing partner-operated fields on the Norwegian continental shelf. It has reserves of 1,147 million barrels of oil equivalent on the Norwegian continental shelf. The company was formerly known as Eni Norge AS and changed its name to Vår Energi AS in December 2018. The company was founded in 1965 and is based in Sandnes, Norway. Vår Energi AS is a subsidiary of Eni International B.V.

Earnings Per Share

As for profitability, VÅR ENERGI has a trailing twelve months EPS of kr2.7.

PE Ratio

VÅR ENERGI has a trailing twelve months price to earnings ratio of 9.64. Meaning, the purchaser of the share is investing kr9.64 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 47.67%.

More news about VÅR ENERGI.

2. PANORO ENERGY (PEN.OL)

0.93% Forward Dividend Yield and 11.06% Return On Equity

Panoro Energy ASA, an independent exploration and production company, engages in the exploration, development, and production of oil and gas in Africa. It holds assets in the Equatorial Guinea, Gabon, Tunisia, and South Africa. The company was incorporated in 2009 and is headquartered in London, the United Kingdom.

Earnings Per Share

As for profitability, PANORO ENERGY has a trailing twelve months EPS of kr1.65.

PE Ratio

PANORO ENERGY has a trailing twelve months price to earnings ratio of 16.3. Meaning, the purchaser of the share is investing kr16.3 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.06%.

Growth Estimates Quarters

The company's growth estimates for the current quarter is 311.4% and a drop 11.3% for the next.

Sales Growth

PANORO ENERGY's sales growth is 262% for the present quarter and 153.2% for the next.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.6%, now sitting on 188.63M for the twelve trailing months.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Mar 8, 2023, the estimated forward annual dividend rate is 0.26 and the estimated forward annual dividend yield is 0.93%.

More news about PANORO ENERGY.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com